Erdanib 4 mg contains Erdafitinib, an oral targeted anticancer therapy belonging to the class of fibroblast growth factor receptor (FGFR) inhibitors. It is specifically developed for the treatment of certain cancers driven by FGFR genetic alterations. By targeting the underlying molecular cause of tumor growth, Erdanib 4 mg provides a precision-based treatment option that helps slow disease progression and improve clinical outcomes in eligible patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active ingredient: Erdafitinib 4 mg

• Dosage form: Oral tablet

Therapeutic Class

• FGFR (Fibroblast Growth Factor Receptor) inhibitor

• Targeted antineoplastic agent

Mechanism of Action

Erdafitinib works by selectively inhibiting FGFR1, FGFR2, FGFR3, and FGFR4 tyrosine kinases. Abnormal activation of FGFR signaling due to gene mutations or fusions can promote uncontrolled cancer cell growth and survival. By blocking FGFR-mediated signaling pathways, Erdanib 4 mg helps suppress tumor cell proliferation, induce cancer cell death, and limit further disease progression. This targeted mechanism allows for more focused anticancer activity compared with conventional chemotherapy.

Indications

Erdanib 4 mg is indicated for the treatment of:

• Locally advanced or metastatic urothelial carcinoma in adult patients with susceptible FGFR2 or FGFR3 genetic alterations, as determined by an approved diagnostic test, following progression on prior platinum-containing chemotherapy

• Other FGFR-driven malignancies as prescribed by an oncologist, based on clinical evidence and treatment protocols

Dosage and Administration

• Treatment is usually initiated at 8 mg once daily, with possible dose adjustments based on serum phosphate levels, efficacy, and tolerability.

• Erdanib 4 mg tablets allow flexible dose titration as directed by the treating physician.

• Tablets should be swallowed whole and may be taken with or without food.

• Regular monitoring of serum phosphate levels and ophthalmologic examinations are required during therapy.

Benefits and Features

• Targeted therapy for FGFR-altered cancers

• Oral administration improves patient convenience and adherence

• Precision-based treatment approach with proven clinical benefit

• May help control tumor growth and prolong progression-free survival

• Enables individualized dosing under specialist supervision

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Erdanib 4 mg may cause hyperphosphatemia; routine monitoring and dietary management are essential.

• Eye disorders, including central serous retinopathy, may occur and require regular eye examinations.

• Use with caution in patients with renal or hepatic impairment.

• Not recommended during pregnancy or breastfeeding unless clearly advised by a specialist.

• Patients should inform their oncologist about all concomitant medications before starting treatment.

Side Effects

Common side effects include hyperphosphatemia, stomatitis, dry mouth, fatigue, diarrhea, nail changes, and eye-related symptoms. Serious adverse reactions are uncommon but may require dose modification or discontinuation.

Storage

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children

Erdanib 4 mg offers a modern, targeted treatment option for patients with FGFR-driven cancers. When used under expert oncological care, it supports a personalized approach to cancer management with meaningful therapeutic benefits.